🔗 Share this article

An underground market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.

Investigational Drug Acquiring Traction Online

The experimental drug, which remains in clinical trials, is being advertised by online personalities for its supposed fat-burning effects. Viewers are urged to contact these accounts privately for source information, while also receiving discount codes.

Active Commerce on Social Networks

Additionally, a flourishing market exists on messaging services, where communities with thousands of members share “before and after” images, injection guides and assertions of rapid UK delivery. Vendors market the drug there before redirecting customers to WhatsApp for purchases.

Learning About The Experimental Drug

This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies indicate it could help patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Healthcare Experts Voice Worries

However, doctors and chemists have cautions that the distribution of what remains an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals injecting products of uncertain source.

Some experts stated the popularity for retatrutide could be linked to the rising price of licensed slimming products such as Mounjaro.

Legal Position and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unlicensed medication that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.

Some content creators try to sidestep the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and distribution can still violate medicines, marketing, and consumer laws, potentially leading to penalties, prosecution or prison.

Service Response and Content Removal

According to the social media company, the service has taken down problematic content and prohibited related keywords and search suggestions. The company said it was committed to maintaining the service safe and investing in enhancing compliance measures.

Digital Marketplace Activities

Research also discovered communities with up to 9,000 participants marketing retatrutide using Telegram's built-in discovery tool, which functions like a public directory. Typing “retatrutide” instantly brings up groups with thousands of members, filled with images of weight loss, glowing testimonials and detailed instructions for mixing or administering at residence.

Within moments of joining one group, a vendor shared contact information, where the majority of transactions take place. The seller provided an instruction manual and guaranteed shipping within two days. When asked whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a image of a alleged testing documentation. None asked about weight, medical conditions or past usage.

Item Details and Pricing

Within these communities, messages show black plastic parcels with Royal Mail labels, stating to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at home with purified liquid, or ready-to-use injectors typically priced at £160 for 20 milligrams. When asked how long a pen should last, sellers give conflicting responses ranging from a several days to “depends on your body”.

Service Oversight and Security Measures

A spokesperson for Telegram stated it actively monitored harmful material on its platform including content that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“Individuals are administering substances they cannot confirm. Although the research behind this drug is valid, these online products may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the increase in interest to recent price rises for authorized weight-loss medications such as Mounjaro. “With prices increasing, individuals are using social media. But fake injections are extremely dangerous. You can’t be certain what’s inside or whether the environment they were made in was clean,” she said.

Her team has previously encountered patients injured by personal administration from unverified suppliers. “We recognize the disappointment, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Producer Statement

A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any government authority globally. “Therefore at this point no one can sell [it] for human use,” they said, adding that any product “misleadingly claiming itself as a company experimental product not yet approved … may subject patients to potentially serious health risks”.